TCK-276

Teijin America, Inc. · Phase 1 active Small molecule

At a glance

Generic name	TCK-276
Also known as	Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitor, TEI-T01276, Placebo
Sponsor	Teijin America, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TCK-276 CI brief — competitive landscape report
TCK-276 updates RSS · CI watch RSS
Teijin America, Inc. portfolio CI